EP Patent

EP2266984A1 — Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis

Assigned to Deutsches Krebsforschungszentrum DKFZ · Expires 2010-12-29 · 15y expired

What this patent protects

Compounds according to the general formula (I) their solvates, hydrates, esters and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

USPTO Abstract

Compounds according to the general formula (I) their solvates, hydrates, esters and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP2266984A1
Jurisdiction
EP
Classification
—
Expires
2010-12-29
Drug substance claim
No
Drug product claim
No
Assignee
Deutsches Krebsforschungszentrum DKFZ
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.